Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 18 Apr, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Recent Articles
- China Humanoid Robot Half-Marathon to Showcase Big Advances
- $166 Billion in Tariff Refunds to Begin Processing Monday
- Top Kpop Agencies Mull Creating Coachella-Style Global Festival
- Apple's Q1 China iPhone Sales Surged 20%
- Robotic Exoskeleton Helps Elderly Hong Kong Fire Survivors Climb Back for Belongings
- Walmart Flipkart to Tap India Ticketing Market on Live Events Boom
- China Shows Off High-Speed Rail to Viet Leader, Offers Loan, Tech
- Polestar's Q4 Revenue Jumps, Narrows Loss
- Hormuz Strait Open Since Lebanon Deal Says Iran
- EU Exports Fell Again in February on US Tariffs